Field evaluation of novel experimental nootkatone-based products for control of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae)
Journal of Medical Entomology · 01.07.2026 · 63 (4)
DOI: 10.1093/jme/tjag105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Entomology, online erschienen am 15.07.2026. Verfasst von Chantal Sengsourinho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vector-borne Disease, Woodward Hall, University of Rhode Island, Kingston, RI, USA. Hauptthemen laut MEDLINE: Amblyomma, Ixodes, Polycyclic Sesquiterpenes, Tick Control. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ACL HHS, CDC HHS, New England Center of Excellence in Vector-borne Disease.
Abstract (Originalsprache)
A total of eight nature-based products were tested against nymphal blacklegged ticks Ixodes scapularis Say or lone star ticks, Amblyomma americanum (L.) during the summers of 2023 and 2024. Field trials were performed using a micro-plot arena system in a natural field setting. The arena system has previously been used to successfully evaluate products against blacklegged nymphs and was modified for use with lone star nymphs. One of the eight products evaluated in the study, the commercially available BugArmor Zero-Bite, did not exhibit any significant tick-killing activity. The other seven products were nootkatone-based (NootkaSHIELD™) experimental formulations provided by the Swiss company Evolva and still in the product-development process. Of those samples, Evo A (10% nootkatone) and Evo C (10% nootkatone) provided over 94% knockdown control (efficacy within the first two weeks of application) of blacklegged ticks, and 81.2% and 91.0% knockdown control of lone star ticks, respectively. Both formulations also displayed significant residual control (efficacy after 2 weeks post treatment) but results for Evo A (10% nootkatone) varied greatly between 2023 and 2024. Evo B (10% nootkatone) also demonstrated high levels of efficacy, with 78.5% knockdown control and 80.8% residual control. Treatments using the three NootkaSHIELD™ formulations containing 3% nootkatone all resulted in knockdown efficacies below 45%. The results of this study suggest that NootkaSHIELD™ products containing 10% nootkatone are promising candidates for future commercial availability to control ticks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vector-borne Disease, Woodward Hall, University of Rhode Island, Kingston, RI, USA.
- Department of Plant Sciences and Entomology, Woodward Hall, University of Rhode Island, Kingston, RI, USA.
ORCID-Profile: Alexis White, Steven R Alm, Thomas N Mather
Förderung
- ACL HHS
- CDC HHS
- New England Center of Excellence in Vector-borne Disease
- Centers for Disease Control and Prevention
Zitieren
APA
Sengsourinho, C., Dyer, M. C., White, A., Alm, S. R., & Mather, T. N. (2026). Field evaluation of novel experimental nootkatone-based products for control of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae). Journal of Medical Entomology, 63(4). https://doi.org/10.1093/jme/tjag105
Vancouver
Sengsourinho C, Dyer MC, White A, Alm SR, Mather TN. Field evaluation of novel experimental nootkatone-based products for control of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae). Journal of Medical Entomology. 2026;63(4). doi:10.1093/jme/tjag105
BibTeX
@article{Sengsourinho2026,
author = {Sengsourinho, Chantal and Dyer, Megan C and White, Alexis and Alm, Steven R and Mather, Thomas N},
title = {Field evaluation of novel experimental nootkatone-based products for control of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae)},
journal = {Journal of Medical Entomology},
year = {2026},
volume = {63},
number = {4},
doi = {10.1093/jme/tjag105}
}
EUVIMED